Arrowhead Pharmaceuticals Inc $ 56.72 1.98 (3.62%)
On watch
Volume:
2,044,277
Avg Vol (1m):
1,820,561
Market Cap $:
5.80 Bil
Enterprise Value $:
5.54 Bil
P/E (TTM):
0.00
P/B:
11.76
Financial Strength | 8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 13.43 | ||
| Equity-to-Asset | 0.89 | ||
| Debt-to-Equity | 0.04 | ||
| Debt-to-EBITDA | -0.76 | ||
| Piotroski F-Score | 1 | ||
| Altman Z-Score | 54.65 | ||
| Beneish M-Score | 8.01 | ||
| WACC vs ROIC | |||
Profitability Rank | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -27.01 | ||
| Net Margin % | -19.75 | ||
| ROE % | -6.23 | ||
| ROA % | -5.11 | ||
| ROC (Joel Greenblatt) % | -102.02 | ||
| 3-Year Revenue Growth Rate | 729.5 |
ARWR
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Forward PE Ratio | 91.74 | ||
| PB Ratio | 11.76 | ||
| PS Ratio | 46.04 | ||
| EV-to-EBIT | -165.74 | ||
| EV-to-EBITDA | -196.65 | ||
| EV-to-Revenue | 44.77 | ||
| Current Ratio | 7.37 | ||
| Quick Ratio | 7.37 | ||
| Days Sales Outstanding | 64.03 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 12.15 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 41.71 | ||
| Price-to-Median-PS-Value | 0.38 | ||
| Earnings Yield (Greenblatt) % | -0.6 |